Lornoxicam是一种口服有效的奥昔康类非甾体抗炎药,具有镇痛、抗炎、解热及抗癌活性。它通过强力抑制COX-1和COX-2,并抑制iNOS与IL-6的产生,进而发挥抗炎作用,同时,它还能抑制肿瘤细胞增殖与迁移并诱导其凋亡,可用于炎症性疼痛、结直肠癌和乳腺癌的研究。
|
英文别名 (English Synonym) |
Lornoxicam |
|
中文名称 (Chinese Name) |
氯诺昔康 |
|
靶点 (Target) |
COX |
|
通路 (Pathway) |
Neuroscience |
|
CAS号 (CAS NO.) |
70374-39-9 |
|
分子式 (Formula) |
C13H10ClN3O4S2 |
|
分子量 (Molecular Weight) |
371.82 |
|
纯度 (Purity) |
≥98% |
|
溶解性 (Solubility) |
溶于DMSO |
-25~-15℃保存，有效期3年
[1] Berg J, Fellier H, Christoph T, Grarup J, Stimmeder D. The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res. 1999 Jul,48(7):369-79. doi: 10.1007/s000110050474. PMID: 10450786.[2]Bianchi M, Panerai AE. Effects of lornoxicam, piroxicam, and meloxicam in a model of thermal hindpaw hyperalgesia induced by formalin injection in rat tail. Pharmacol Res. 2002 Feb,45(2):101-5. doi: 10.1006/phrs.2001.0921. PMID: 11846620.
